Edesa Biotech reports Q3 net loss $1.7M; ARDS drug selected for U.S. government study

Edesa Biotech, Inc.

Net loss of $1.7M ($0.52/shr) vs $2.0M ($0.68/shr) a year ago; nine-month loss $5.2M ($1.64/shr).
Cash $2.0M; working capital $0.7M; received $300K post-quarter from Canadian govt SIF fund.
EB05 (paridiprubart) chosen for HHS-funded ARDS platform study; Edesa supplies drug and tech support.
Preparing IND for Phase 2 vitiligo study of anti-CXCL10 technology in moderate-to-severe patients.
Q3 operating expenses $1.9M, down $0.2M YoY; R&D $0.9M, down $0.1M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.